Surviving PEA in Roanoke (SPEAR) Study

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 342 participants.

Also called NCT05283850

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 342 participants (planned count) (from the registry)
Sponsor
Carol Bernier (from the registry)
Registry
  • NCT NCT05283850
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05283850. Randomized; quadruple masking; primary purpose treatment. Start 2022-02-16 (actual); primary completion 2027-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Surviving PEA in Roanoke (SPEAR) Study
Acronym
SPEAR
Condition
Pulseless Electrical Activity
Intervention (Drug)
High Calcium, Low Sodium (HCLS) Crystalloid Therapy
Intervention (Drug)
High Calcium, High Sodium (HCHS) Crystalloid Therapy
Lead sponsor
Carol Bernier (class: other)
Collaborator
Virginia Polytechnic Institute and State University (class: other)

Record details

Record id
cardio:ct-nct05283850
Content hash
a8d126c2e9b8886cbd42e16dfb63410e998b45ddb26b48f37687dc098ee8f346